Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q4 FY20 results · Jan–Mar 2020
Jubilant Pharmova reported revenue from operations of ₹2,391.41 crore (up 0.2% from Q4 FY19) and net profit of ₹260.49 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,391.41 | 2,385.58 | +0.2% | 2,315.21 | +3.3% |
| Other income | 19.44 | (6.58) | Turned profit | 6.03 | +222.4% |
| Total income | 2,410.85 | 2,379.00 | +1.3% | 2,321.24 | +3.9% |
| Profit before tax | 355.95 | (39.98) | Turned profit | 293.32 | +21.4% |
| Net profit for the period | 260.49 | (100.65) | Turned profit | 203.38 | +28.1% |
| EPS, basic (₹) | 16.35 | (6.38) | Turned profit | 12.77 | +28.0% |
| Net margin (%) | 10.9 | -4.2 | 8.8 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 791.36 | 865.12 | −8.5% | 801.18 | −1.2% |
| Other income | 82.69 | 4.83 | 17x | 5.52 | 15x |
| Total income | 874.05 | 869.95 | +0.5% | 806.70 | +8.3% |
| Profit before tax | 110.36 | 6.39 | 17x | 34.96 | +215.7% |
| Net profit for the period | 111.18 | 7.44 | 15x | 34.63 | +221.1% |
| EPS, basic (₹) | 6.98 | 0.47 | 15x | 2.17 | +221.7% |
| Net margin (%) | 14.0 | 0.9 | 4.3 |
Consolidated
- Filed with BSE
- 30 May 2020, 13:15 IST
- Board meeting
- 29 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 May 2020, 13:15 IST
- Board meeting
- 29 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE